Preparation of cyclohexene isotopologues and stereoisotopomers from benzene

Jacob A. Smith, Katy B. Wilson, Reilly E. Sonstrom, Patrick J. Kelleher, Kevin D. Welch, Emmit K. Pert, Karl S. Westendorff, Diane A. Dickie, Xiaoping Wang, Brooks H. Pate and W. Dean Harman ()
Additional contact information
Jacob A. Smith: University of Virginia Department of Chemistry
Katy B. Wilson: University of Virginia Department of Chemistry
Reilly E. Sonstrom: University of Virginia Department of Chemistry
Patrick J. Kelleher: University of Virginia Department of Chemistry
Kevin D. Welch: University of Virginia Department of Chemistry
Emmit K. Pert: University of Virginia Department of Chemistry
Karl S. Westendorff: University of Virginia Department of Chemistry
Diane A. Dickie: University of Virginia Department of Chemistry
Xiaoping Wang: Oak Ridge National Laboratory
Brooks H. Pate: University of Virginia Department of Chemistry
W. Dean Harman: University of Virginia Department of Chemistry

Nature, 2020, vol. 581, issue 7808, 288-293

Abstract: Abstract The hydrogen isotopes deuterium (D) and tritium (T) have become essential tools in chemistry, biology and medicine1. Beyond their widespread use in spectroscopy, mass spectrometry and mechanistic and pharmacokinetic studies, there has been considerable interest in incorporating deuterium into drug molecules1. Deutetrabenazine, a deuterated drug that is promising for the treatment of Huntington’s disease2, was recently approved by the United States’ Food and Drug Administration. The deuterium kinetic isotope effect, which compares the rate of a chemical reaction for a compound with that for its deuterated counterpart, can be substantial1,3,4. The strategic replacement of hydrogen with deuterium can affect both the rate of metabolism and the distribution of metabolites for a compound5, improving the efficacy and safety of a drug. The pharmacokinetics of a deuterated compound depends on the location(s) of deuterium. Although methods are available for deuterium incorporation at both early and late stages of the synthesis of a drug6,7, these processes are often unselective and the stereoisotopic purity can be difficult to measure7,8. Here we describe the preparation of stereoselectively deuterated building blocks for pharmaceutical research. As a proof of concept, we demonstrate a four-step conversion of benzene to cyclohexene with varying degrees of deuterium incorporation, via binding to a tungsten complex. Using different combinations of deuterated and proteated acid and hydride reagents, the deuterated positions on the cyclohexene ring can be controlled precisely. In total, 52 unique stereoisotopomers of cyclohexene are available, in the form of ten different isotopologues. This concept can be extended to prepare discrete stereoisotopomers of functionalized cyclohexenes. Such systematic methods for the preparation of pharmacologically active compounds as discrete stereoisotopomers could improve the pharmacological and toxicological properties of drugs and provide mechanistic information related to their distribution and metabolism in the body.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/s41586-020-2268-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:581:y:2020:i:7808:d:10.1038_s41586-020-2268-y

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-020-2268-y

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().